Correlation Between Arcus Biosciences and Tempest Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Arcus Biosciences and Tempest Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Arcus Biosciences and Tempest Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Arcus Biosciences and Tempest Therapeutics, you can compare the effects of market volatilities on Arcus Biosciences and Tempest Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Arcus Biosciences with a short position of Tempest Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Arcus Biosciences and Tempest Therapeutics.

Diversification Opportunities for Arcus Biosciences and Tempest Therapeutics

0.17
  Correlation Coefficient

Average diversification

The 3 months correlation between Arcus and Tempest is 0.17. Overlapping area represents the amount of risk that can be diversified away by holding Arcus Biosciences and Tempest Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Tempest Therapeutics and Arcus Biosciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Arcus Biosciences are associated (or correlated) with Tempest Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Tempest Therapeutics has no effect on the direction of Arcus Biosciences i.e., Arcus Biosciences and Tempest Therapeutics go up and down completely randomly.

Pair Corralation between Arcus Biosciences and Tempest Therapeutics

Given the investment horizon of 90 days Arcus Biosciences is expected to generate 0.64 times more return on investment than Tempest Therapeutics. However, Arcus Biosciences is 1.56 times less risky than Tempest Therapeutics. It trades about 0.01 of its potential returns per unit of risk. Tempest Therapeutics is currently generating about -0.11 per unit of risk. If you would invest  1,583  in Arcus Biosciences on September 23, 2024 and sell it today you would lose (33.00) from holding Arcus Biosciences or give up 2.08% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Arcus Biosciences  vs.  Tempest Therapeutics

 Performance 
       Timeline  
Arcus Biosciences 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Arcus Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Arcus Biosciences is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors.
Tempest Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Tempest Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Arcus Biosciences and Tempest Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Arcus Biosciences and Tempest Therapeutics

The main advantage of trading using opposite Arcus Biosciences and Tempest Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Arcus Biosciences position performs unexpectedly, Tempest Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tempest Therapeutics will offset losses from the drop in Tempest Therapeutics' long position.
The idea behind Arcus Biosciences and Tempest Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Complementary Tools

Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets